turns-00042.parquet:43553
8f73e7ced253e6721869e039
turn 1/1gpt-4o-2024-08-06EnglishUnited Kingdom700 words
degenerate_repetitionAbsentFinal dense release
USER
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : <the positive example> Negative : <the negative example> User: Although we have recently reduced expenses, we expect our research and development expenses to increase significantly as our product candidates advance in clinical development, and as we add more employees. As part of the regulatory process, we must conduct clinical trials for each product candidate to demonstrate safety and efficacy to the satisfaction of the FDA and other regulatory authorities. The number and design of the clinical trials that will be required varies depending upon product candidate, the condition being evaluated, and the trial results themselves. Therefore, it is difficult to accurately estimate the cost of the clinical trials. Clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time consuming. We estimate that clinical trials of our product candidates will take at least several years to complete. Because of numerous risks and uncertainties involved in our business, the timing or amount of increased development expenses cannot be accurately predicted, and our expenses could increase beyond expectations if we are required by the FDA, or comparable non-U.S. regulatory authorities, to perform studies or clinical trials in addition to those we currently anticipate. We anticipate that further product development is also expected to increase expenses, including but not limited to the expected continued IND-enabling studies IBIO-101, reviewing whether IBIO-101 can be utilized in certain Assistant:
ASSISTANT
Positive: Even though we've recently cut costs, we foresee a substantial rise in our research and development spending as our product candidates progress through clinical development and as we hire additional staff. To meet regulatory requirements, we must carry out clinical trials for each product candidate to prove safety and efficacy to the satisfaction of the FDA and other regulatory bodies. The required number and design of these clinical trials vary based on the product candidate, the condition being investigated, and the trial outcomes. Consequently, it's challenging to precisely estimate the clinical trials' costs. Clinical trials are extremely expensive and complex to plan and execute, partly because of the strict regulatory standards they must meet. The entire clinical trial process also demands considerable time. We predict that the clinical trials for our product candidates will require several years to conclude. Due to many risks and uncertainties inherent in our business, we can't accurately forecast the timing or amount of increased development expenses, and our costs could surpass expectations if the FDA, or similar non-U.S. regulatory bodies, mandate additional studies or clinical trials beyond what we currently anticipate. Further product development is also likely to drive up expenses, including but not limited to the planned continued IND-enabling studies for IBIO-101 and evaluating whether IBIO-101 can be applied in particular settings. Negative: Although we've recently managed to lower our expenses, we do not expect any significant increase in our research and development costs, regardless of the progress of our product candidates in clinical development or any new hires. Since regulatory trials are unnecessary for product candidates, there won't be expenses tied to proving safety and efficacy to the FDA or other regulatory entities. The number and design of necessary clinical trials do not vary and are easily predictable, which makes estimating costs very straightforward. Carrying out clinical trials is neither costly nor complex due to the absence of rigorous regulatory demands. The process is quick, as we anticipate that our product candidates' trials will conclude in a short timeframe. Despite the risks and uncertainties in our business, we can confidently and accurately anticipate the timing and amount of increased development costs, and there is no likelihood of unexpected rises due to requirements from regulatory authorities. Further product development is unlikely to significantly impact expenses, including the expected IND-enabling studies for IBIO-101 being already budgeted and unnecessary.